TMCnet - World's Largest Communications and Technology Community



RedPath Announces Presentations at 2014 Digestive Disease Week Meeting
[May 02, 2014]

RedPath Announces Presentations at 2014 Digestive Disease Week Meeting

PITTSBURGH --(Business Wire)--

RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, announced today that data from The National Pancreatic Cyst Registry, a multi-institutional prospective study of 492 patients with pancreatic cysts, has been accepted for oral presentation at the Digestive Disease Week (DDW) Annual Meeting taking place May 3-6, 2014, at McCormick Place in Chicago.

Results from the study show that, when cytology results are non-malignant, integrated molecular pathology (IMP) can accurately differentiate cysts with low versus high malignant potential by incorporating DNA molecular analyses with first-line tests (cytologic atypia, CEA, imaging).

Dr. Thomas Kowalski, Director of Gastroenterology and Associate Professor of Medicine at Thomas Jefferson University will present the data on Tuesday, May 6 at 2:20pm (CT).

In addition, research data on the use of IMP in patient management of pancreatic cysts will be presented in a poster on Monday, May 5, 2014, and data on the use of IMP in Barrett's Esophagus will be presented in a poster on Tuesday, May 6, 2014.

Details of the presentations are as follows:

Title: Management strategy of pancreatic cys patients based on integrated molecular pathology in 492 patients: The final results of a multicenter study.

Number: Mo1439
Poster session: ASGE - EUS 2
Authors: Mohammad Al-Haddad, MD, et al
Session date: Monday, May 5, 2014
Location: South Hall

Title: Clinical utility of using second-line integrated molecular pathology testing in addition to first-line test algorithms to determine the malignant potential of pancreatic cysts.
Number: 987
Session title: Pancreatic cancer: Now and in the future
Presenter: Thomas Kowalski, MD, Director of Gastroenterology, Associate Professor of Medicine, Thomas Jefferson University
Session date: Tuesday, May 6, 2014
Presentation time: 2:20pm (CT)
Location: S102D

Title: Mutational load as a predictor of progression in Barrett's Esophagus: a longitudinal study.
Number: Tu1307
Poster session: ASGE - Esophagus
Authors: Ebubekir Daglilar, MD, et al
Session date: Tuesday, May 6, 2014
Location: South Hall

About RedPath Integrated Pathology

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath's patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.

The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit or contact Andrew Mignatti at 412-224-6100.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy